



The Core Summit Agenda Main Auditorium, Aga Khan University, Karachi

Day 1- 17th February 2025

|--|

| Opening Ceremony | |
|---------------------|---|
| Time | Title |
| 09:00 AM - 09:10 AM | Welcome Address & Overview of Summit Objectives |
| | Tabling the Summit Resolution |
| 09:10 AM – 09:30 AM | High level messages: |
| | Shaping the Future of Clinical Trials in Pakistan |

| Session 1- Pakistan Clinical Trials Landscape | |
|---|--|
| Time | Title |
| 09:30 AM- 09:45 AM | Pakistan Clinical Trials Landscape Report |
| 09:45 AM- 10:00 AM | Disease Patterns in Pakistan and Their Impact on Clinical Trials |
| 10:00 AM - 10:30 AM | Focus Therapeutic Areas- The Role of Registries |
| | Cardiovascular diseases |
| | Diabetes Mellitus |
| | Oncology |
| 10:30 AM - 11:00 AM | Panel Discussion |
| 11:00 AM- 11:30 AM | Networking Break |

| Session 2: WHO Plenary Session- Best Practices to Strengthen Clinical Trials | |
|--|--|
| Time | Title |
| 11:30 AM- 11:55 AM | WHO Normative Guidance for Best Practices in Clinical Trials |
| 11:55 AM – 12:20 PM | Maturity Frameworks for Clinical Trials Unit |
| 12:20 PM- 12:45 PM | Preparing the Region for Large Multinational Clinical Trials |
| 12:45 PM - 01:00 PM | Q/A session |





01:00 PM- 02:00 PM Lunch & Networking

| Session 3- Regulatory Framework Analysis | |
|--|--|
| Time | Title |
| 02:00 PM - 03:15 PM | Global Regulatory Insights-Best Practices: |
| | 1. Pakistan |
| | 2. UK MHRA |
| | 3. Malaysia |
| | 4. Egypt |
| | 5. UAE |
| | 6. Perspectives from FDA |
| 03:15 PM - 03:45 PM | Panel Discussion |
| | Way Forward – Insights from Authorities on Pressing Issues |
| | Key expectations from regulatory authorities. |
| | Addressing pressing challenges in clinical trials: compliance, patient recruitment, and ethical practices. |
| | Strategies for future collaboration and harmonization of regulations. |
| 03:45 PM- 04:15 PM | Networking Break |

| | Session 4- Ethical Considerations in Clinical Trials |
|------------------------|---|
| Time | Title |
| 04:15 PM- 04:30 PM | Role Of National Bioethics Committee- Advancing Ethical Efficiency |
| | Too many ethics committees vs single IRB policy |
| | Strategies to explore to avoid repetitive ethics review processes |
| 04:30 PM- 04:45 PM | Rigorous yet efficient ethics review Emergency Use Authorizations and Fast-Track Trials: Ethical Dilemmas |
| 04.30 FIVI- 04.43 FIVI | |
| | Balancing speed and rigor during public health crises The male of others in fact the philips are said as a sundath are provided. |
| | • The role of ethics in fast-tracking vaccines and therapeutics |
| | Lessons from COVID-19 trials |
| 04:45 PM- 05:00 PM | The Work of AKU Ethics Review Committees in Enhancing Clinical Trials Activity |
| 05:00 PM- 05:15 PM | Balancing Risk and Benefit in Trial Design |
| | Case studies of ethical dilemmas in high-risk trials |
| | Strategies for minimizing harm and maximizing benefit |
| | Adaptive trial designs and their ethical implications |
| 05:15 PM- 05:30 PM | Equity in Participant Recruitment |
| | Addressing disparities in clinical trial participation |
| | Recruiting underrepresented populations ethically and effectively |
| | Lessons from global trials on equitable recruitment practices |
| 05:30 PM- 05:45 PM | Q & A session |





| Session 5- Building Clinical Trials Ecosystems | |
|--|--|
| Time | Title |
| 05:45 PM- 06:30 PM | Building Clinical Trials Consortia- Case Studies Form Successful Eco Systems. |
| | Infectious Diseases |
| | Cardio-Metabolic |
| | Oncology |
| | Reproductive Health |
| | Examples from the US |
| 06:30 PM- 07:00 PM | Panel Discussion |
| | A Roadmap to Creating a Sustainable Clinical Trial Ecosystem in Pakistan |
| | Regulatory Framework |
| | Capacity Building |
| | Public Awareness and Engagement |
| | Incentives for Industry Which strategies should be adopted to strangthen collaborative research? |
| | Which strategies should be adopted to strengthen collaborative research? Which mechanism should be devised to increase opportunities for collaboration between different research stakeholders. |
| | How can we address barriers to cooperation required for networking between countries and within Pakistan? |
| 07:00 PM- 07:15 PM | Summary Of Discussion and Closing Remarks for Day 1 |
| 07:15 PM | Dinner |





Day 2- 18th February 2025

| 08:30 AM – 09:00 AM | Tea & Coffee |
|---------------------|--------------|
| | |

| Session 6- Stakeholders Collaboration | |
|---------------------------------------|--|
| Time | Title |
| 09:00 AM- 09:30 AM | Sponsors' Experience with Clinical Trials in Pakistan |
| | Pakistan Clinical Trial Units |
| | Availability of Patients |
| | Experience with PIs and Site Staff |
| | Potential for Future Studies in Pakistan |
| 09:30 AM- 10:00 AM | The Evolving Role of CROs in Fostering Multistakeholder Synergy in Clinical Trials |
| 10:00 AM- 10:30 AM | Enhancing the Role of Clinical Trial Units in Collaborative Partnerships: |
| | Challenges and Opportunities |
| 10:30 AM- 11:00 AM | Panel Discussion |
| 11:00 AM- 11:30 AM | Networking Break |

| | Session 7- Engaging Patients and Communities |
|--------------------|---|
| Time | Title |
| 11:30 AM- 11:50 AM | Bridging Communities and Research: Facilitating Community-Based Clinical Trials |
| | Challenges and support needed to support community-based studies |
| 11:50 AM- 12:10 PM | Public and Patient Engagement |
| 12:10 PM- 12:40 PM | Plenary Talk: |
| | Upscaling Human Capacity in Clinical Trials |
| | Capacity building & Modern approach to cope with challenging times |

| Session 8- Transforming Clinical Trials: Strategies for Innovation, Efficiency, and Global | | |
|--|--|--|
| | lmpact | |
| Time | Title | |
| 12:40 PM- 01:00 PM | Streamlining Clinical Trials-Adopting a Risk-Based Approach and Proportionate Approaches for Effective Trial Management | |
| | Risk-Based Resource Allocation Proportionate Management Practices WHO, ICH E6(R3), and E8(R1) alignment to design, manage, and monitor trials to maintain integrity and participant safety | |
| 01:00 PM- 01:15 PM | From Vision to Reality: Enabling High-Impact Clinical Trials in Emerging Markets | |





| | Challenges to launch large regional clinical trials. How can specific hurdles (regulatory, logistical, organizational) be overcome Establishment of large clinical trials network |
|--------------------|---|
| 01:15 PM- 01:30 PM | Revolutionizing Clinical Trials: Data Science, Machine Learning, and AI |
| 01:30 PM- 02:15 PM | Lunch & Networking |

| Session 9- Building Research Excellence | | |
|---|---|--|
| Time | Title | |
| 02:15 PM – 02:45 PM | Developing Research Capacities | |
| | How can we enhance the capacities to conduct robust, high-impact clinical trials? Different areas of specialization and skills that are needed for each role. Challenges to talent recruitment and retention Incentives to support and increase the number of local researchers. | |
| 02:45 PM - 03:15 PM | Becoming a Clinical Trial Site and PI Selection Criteria | |
| | Hands-on guidance and actionable strategies. | |

| 03:15 PM - 03:30 PM | Summary of Discussion and Closing Remarks |
|---------------------|---|
| | |